SecBot SecBot

WVE drug pipeline

Wave Life Sciences, Inc. · 3 rated drugs
$2.87
−8.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 1b/2a (RestorAATion-2); registrational Phase 3 planned
Time to marketIf the registrational trial starts in 2027, the 1-year interim analysis for potential accelerated approval could come in 2028, with full approval possible in 2029. This is an estimate; no trial start date has been announced.

WVE-006 Updated Oct 27

What to watch

The next catalyst is the 600 mg monthly multidose cohort data from the RestorAATion-2 trial, expected in Q4 2026 (any day now). Positive data reinforcing the MZ-like phenotype and safety profile would support the registrational trial design and could drive the stock; disappointing results would raise questions about the accelerated approval timeline. The registrational trial itself has not yet started, so the path to market is still 2+ years away.

Bull case
  • WVE-006 is a first-in-class RNA editing therapy that corrects the root cause of AATD, addressing both lung and liver manifestations, no currently approved therapy does both.
  • Phase 1b/2a RestorAATion-2 data showed achievement of the protective MZ-like phenotype with monthly subcutaneous dosing, with 71% reduction in toxic Z-AAT and 64% wild-type M-AAT.
  • FDA aligned on a streamlined registrational pathway in October 2026: a single 2-year trial with a 1-year interim analysis that could support accelerated approval based on biomarkers, with no separate confirmatory study required.
Bear case
  • GSK returned full global rights to Wave in February 2026 after September 2025 data came below analyst expectations, a negative signal about the asset's commercial potential from a deep-pocketed partner.
  • JP Morgan downgraded WVE to Neutral in September 2026, and several large holders (T. Rowe Price, Citadel, Federated Hermes) sharply trimmed or exited their positions in Q2 2026.
  • The FDA required a new 2-year registrational trial rather than allowing the existing RestorAATion-2 data to support approval, meaning the path to market is longer and more expensive than some investors hoped.
● neutral
Impact
PhasePhase 1/2a
Time to marketSeveral years away — still in Phase 1/2a with no regulatory filing submitted. If Phase 2a data are positive, a Phase 3 program would likely take 2-3+ years, followed by an FDA submission. Best-case timeline to potential approval is likely 2029-2030 at the earliest.

WVE-007 inhbe galnac-sirna Updated Oct 27

What to watch

The next catalyst is the initiation of the post-incretin maintenance trial, expected in Q4 2026 (imminent). Beyond that, Phase 2a combination-trial data (WVE-007 + tirzepatide) and 12-month monotherapy data are the next meaningful readouts, though no specific dates are set. A positive maintenance-trial initiation or combination data could re-rate the stock from its depressed levels, but the high short interest (~10.7% of outstanding) and intense GLP-1 competition mean any miss would likely be punished severely.

Bull case
  • Novel muscle-sparing mechanism: WVE-007 targets fat burning directly (silencing INHBE/Activin E) rather than appetite, preserving lean mass while GLP-1s cause muscle loss, a key differentiator for the massive obesity market.
  • Phase 1 data showed a single 240 mg dose reduced visceral fat by ~14% at 6 months (placebo-adjusted), with visceral fat-to-muscle ratio improvement (-16.5%) beating semaglutide at the same time point (-12.2%).
  • Once- or twice-yearly dosing potential (vs weekly GLP-1 injections) could dramatically improve patient adherence and convenience, addressing a major real-world problem where ~55% of tirzepatide patients discontinue.
Bear case
  • Intense competition from Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound/Mounjaro), both have massive commercial infrastructure and next-gen oral candidates advancing.
  • Phase 1 weight loss was modest (~0.9% body weight reduction at 6 months), which disappointed the market and triggered a ~56% single-day stock crash in December 2025.
  • Stock is down ~81% YTD and trades near its 52-week low of $3.04, reflecting deep investor skepticism about the drug's commercial viability in a crowded obesity market.
● neutral
Impact
PhasePreclinical
Time to marketAt least 5-7 years, assuming successful CTA filing in Q4 2026, Phase 1 initiation in 2027, and multiple subsequent clinical trial phases before potential approval.

WVE-008 Updated Oct 27

What to watch

The next catalyst for WVE-008 is the CTA filing expected in Q4 2026 (by end of December 2026). A successful filing would transition the program from preclinical to clinical development and validate Wave's RNA editing platform in a second indication after WVE-006. Investors should watch for the actual filing announcement and any details on the planned Phase 1 trial design. The stock also has other near-term catalysts including WVE-006's regulatory pathway and WVE-007 obesity data.

Bull case
  • WVE-008 is a potential first-in-class, disease-modifying RNA editing therapy for PNPLA3 I148M liver disease, targeting an estimated ~9 million homozygous patients in the U.S. and Europe with high unmet need.
  • Wave's RNA editing platform (AIMers) has already demonstrated clinical proof-of-mechanism with WVE-006 in AATD, de-risking the technology for WVE-008.
  • The CTA filing is on track for Q4 2026 (within ~2 months), a near-term catalyst that would move the program into clinical development.
Bear case
  • WVE-008 is still preclinical with no human data, the CTA filing is a regulatory step, not a data readout, and clinical failure risk remains high.
  • Competition is emerging: J&J's PNPLA3 siRNA (JNJ-75220795) has already completed Phase 1 trials showing liver fat reduction, and ProQR is developing a competing RNA editing approach for the same target.
  • Wave Life Sciences has a history of high cash burn (Q3 2026 net loss of $61.9M) and the stock trades near its 52-week low of $3.04, well below the 52-week high of $21.73, reflecting market skepticism about pipeline execution.

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
WVE-006A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATDPhase 2Active not recruiting24Sep 2026
WVE-004 10 mg Q12WOpen-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)Phase 2Terminated · results8Jun 27, 2023